$5.39
5.44% yesterday
Nasdaq, Apr 04, 10:00 pm CET
ISIN
US46565G1040
Symbol
ITOS
Sector
Industry

ITeos Therapeutics Inc Stock price

$5.39
-1.46 21.31% 1M
-4.63 46.21% 6M
-2.29 29.82% YTD
-7.05 56.67% 1Y
-28.42 84.06% 3Y
-13.66 71.71% 5Y
-13.66 71.71% 10Y
Nasdaq, Closing price Fri, Apr 04 2025
-0.31 5.44%
ISIN
US46565G1040
Symbol
ITOS
Sector
Industry

Key metrics

Market capitalization $205.87m
Enterprise Value $-283.68m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 2.84
EV/Sales (TTM) EV/Sales -8.11
P/S ratio (TTM) P/S ratio 5.88
P/B ratio (TTM) P/B ratio 0.33
Revenue growth (TTM) Revenue growth 177.89%
Revenue (TTM) Revenue $35.00m
EBIT (operating result TTM) EBIT $-159.53m
Free Cash Flow (TTM) Free Cash Flow $-99.81m
Cash position $494.65m
EPS (TTM) EPS $-3.49
P/E forward negative
P/S forward 27.82
EV/Sales forward negative
Short interest 6.50%
Show more

Is ITeos Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

ITeos Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a ITeos Therapeutics Inc forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a ITeos Therapeutics Inc forecast:

Buy
100%

Financial data from ITeos Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
35 35
178% 178%
100%
- Direct Costs 1.24 1.24
41% 41%
4%
34 34
188% 188%
96%
- Selling and Administrative Expenses 48 48
3% 3%
137%
- Research and Development Expense 144 144
28% 28%
412%
-158 -158
5% 5%
-452%
- Depreciation and Amortization 1.24 1.24
41% 41%
4%
EBIT (Operating Income) EBIT -160 -160
6% 6%
-456%
Net Profit -134 -134
19% 19%
-384%

In millions USD.

Don't miss a Thing! We will send you all news about ITeos Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ITeos Therapeutics Inc Stock News

Neutral
GlobeNewsWire
10 days ago
WATERTOWN, Mass. and GOSSELIES, Belgium, March 25, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the poster presentations of preclinical data on EOS-215, a potential best-in-class antibody targeting TREM2, and a...
Neutral
GlobeNewsWire
about one month ago
- Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25 - Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025 - Completed enrollment of second dose cohort of EOS-984 + pembrolizumab combination in ongoing Phase 1 trial - EOS-215 Phase 1 trial TRM-010 patient enrollment anticipated to begin in 2Q25 - Cash balance and inv...
Positive
Seeking Alpha
about one month ago
iTeos' lead molecule, Belrestotug, shows promising efficacy in trials despite setbacks in the anti-TIGIT space, with significant partnerships and a strong cash position. The stock has suffered due to failures of similar molecules from competitors, but iTeos' data remains positive, attracting major investments. Financially, iTeos has a solid runway with a market cap of $255mn and cash reserves n...
More ITeos Therapeutics Inc News

Company Profile

iTeos Therapeutics, Inc. engages in the development of biopharmaceuticals therapeutic products and services. It offers immuno-oncology therapeutics for patients. The company was founded by Michel Detheux in April 2012 and is headquartered in Cambridge, MA.

Head office United States
CEO Michel Detheux
Employees 173
Founded 2012
Website www.iteostherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today